U.S. Markets closed

Eiger BioPharmaceuticals (EIGR) Rises: Stock Climbs 24%

Zacks Equity Research

Eiger BioPharmaceuticals, Inc. EIGR was a big mover last session, as the company saw its shares rise over 24% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $6.25 to $8.00 in the past one-month time frame.

None of the estimates for this stock were revised in the last 30 days and the Zacks Consensus Estimate also remained unchanged. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Currently, Eiger BioPharmaceuticals carries a Zacks Rank #3 (Hold), while its Earnings ESP is positive.

A better-ranked stock in the same industry is Agenus Inc. AGEN, sporting a Zacks Rank #1(Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is EIGR going up? Or down? Predict to see what others think: Up or Down

Today's Stocks from Zacks' Hottest Strategies                                         

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.           

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Agenus Inc. (AGEN) : Free Stock Analysis Report
 
Eiger BioPharmaceuticals, Inc. (EIGR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.